Medtronic aims to raise $1bn in note sale
This article was originally published in Clinica
Medtronic is looking to raise around $1bn through a public note sale. Medtronic will offer $500m of its 2.625% senior notes, due 2016, and $500m of its 4.125% senior notes, due 2021. The firm intends to use the cash for general corporate purposes, which could include the repayment of debts. Last month, Minneapolis, Minnesota-based Medtronic recorded modest growth in its third fiscal quarter, and announced plans to cut up to 2,000 jobs in an attempt to control costs (www.clinica.co.uk, 22 February 2011). In other moves to reduce outgoings, it has also cancelled five contracts worth around $2bn with US healthcare group purchasing organisation (GPO) Novation (www.clinica.co.uk, 1 March 2011). Shortly after that, Medtronic also pulled out of its contract with another GPO, Premier, which covered spinal products. Medtronic now plans to sell these products directly to hospitals.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.